Predictive and prognostic values of preoperative platelet parameters in patients with gynecological tumors

Abstract

Background: Platelets play a role in tumor cell growth, metastasis, and angiogenesis, and the present study aimed to evaluate diagnostic and prognostic values of platelet parameters in patients with gynecological tumors.

Methods: A total of 1062 women were included. Differences of platelet parameters (platelet count [PLT], plateletcrit [PCT], mean platelet volume [MPV], platelet-large cell rate [P-LCR], and platelet distribution width [PDW]) between different categories were analyzed by nonparametric test. The optimal cutoff value was calculated with receiver operating characteristic analysis. Overall survivals were analyzed with Kaplan-Meier method and log-rank tests for univariate analysis.

Results: Platelet count and PCT were significantly increased, and MPV and P-LCR were significantly reduced in malign and benign gynecological tumor groups compared with the controls (P < .001); PDW had no significant differences. There were no significant differences in PLT, PCT, MPV, P-LCR, and PDW between different tumor locations and pathologic types. The optimal cutoff values of PLT, PCT, MPV and P-LCR were 274, 0.26, 10.08, and 24.8 (AUC: 0.661, 0.643, 0.593, 0.562), and PCT had preferable sensibility and specificity (50.84% and 70.42%) in predicting the presence of gynecological tumors. According to survival analysis, increased PLT (≥274 × 10⁹ /L) and PCT (≥0.26), and induced MPV (<10.08 fL) and P-LCR (<24.8%) were associated with shorter overall survival.

Conclusions: Platelet count, PCT, MPV, and P-LCR can be used as preferable auxiliary parameters for predicting the presence of gynecological tumors. Increased PLT and PCT, or decreased MPV and P-LCR indicated a heavier tumor burden and shorter overall survival.

Keywords: diagnosis; gynecological tumors; platelet parameters; prognosis.

Figure 1

ROC curves for PLT, PCT, MPV, and P‐LCR showing sensitivity and 100%‐specificity% of differential diagnosis of gynecological tumors versus normal group. MPV, mean platelet volume; PCT, plateletcrit; P‐LCR, platelet‐large cell rate; PLT, platelet count; ROC, receiver operating characteristic

Figure 2

Influence of PLT, PCT, MPV, and P‐LCR on overall survival by Kaplan‐Meier analysis. A, Kaplan‐Meier curves for OS by PLT in gynecological cancer, P < .0001. B, Kaplan‐Meier curves for OS by PCT in gynecological cancer, P = .001. C, Kaplan‐Meier curves for OS by MPV in gynecological cancer, P = .0072. D, Kaplan‐Meier curves for OS by P‐LCR in gynecological cancer, P = .0379. MPV, mean platelet volume; OS, overall survivals; PCT, plateletcrit; P‐LCR, platelet‐large cell rate; PLT, platelet count